S2M S2Medical AB (publ)
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and Epiprotect, a technology designed to protect and support wound healing by creating an environment for tissue recovery. It also provides Symbiovance, a peptide-based functional skincare; Eyracure, a light-activated peptide technology that repairs damaged hair at the molecular level; and Eiratex, a biosynthetic polymer for wound healing applications. In addition, the company distributes instaQrett; skin substitutes under the EPIPROTECT brand; and BIOPAD, an ivory-white soft sponge. The company was incorporated in 2013 and is headquartered in Linköping, Sweden.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About S2Medical (STO: S2M)
›
S2Medical (STO: S2M) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 0.0032 SEK on 19 November 2026, down 69.2% over 52 weeks. Its 52-week range is 0.0030 SEK to 0.0150 SEK: the price is 78.7% below the high and 6.7% above the low.
Its market capitalisation is 3.90M SEK.
S2Medical reports return on equity of -102.2%, an operating margin of -13.0% and revenue up 7.8% year over year.
It holds more cash than debt, a net cash position of 564.00K SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.